Polycythemia vera (PV) management has a clear therapeutic objective: maintain hematocrit <45% to reduce thrombotic risk. The evidence supporting this threshold is well established, and clinical guidelines are explicit in their recommendations.
Despite this clarity, sustained hematocrit control in routine practice remains inconsistent.
Patients frequently cycle above target values, undergo phlebotomy to correct elevations, and then gradually drift upward again. This reactive pattern, while familiar, does not represent optimal longitudinal disease control. It reflects a broader performance gap in how risk is managed over time.
The educational challenge here is the reliability of maintenance and not awareness of the threshold.
The Reactive Management Pattern
In many settings, hematocrit monitoring remains episodic, with laboratory values reviewed primarily during scheduled visits. When hematocrit exceeds target, phlebotomy may be performed or therapy adjusted before monitoring returns to a routine cadence. This reactive approach can delay recognition of sustained hematocrit instability between visits.
Why? Because this approach treats hematocrit elevation as an event rather than as part of a trajectory.
PV, however, is a chronic myeloproliferative disorder characterized by ongoing risk. Thrombotic events are associated with cumulative exposure to elevated hematocrit, not simply isolated spikes. A management strategy that relies solely on reactive correction may allow repeated periods of suboptimal control.
Education must therefore shift focus from threshold recognition to trajectory stabilization.
Table 1. Reactive Versus Longitudinal Management Approaches
| Management Model | Clinical Behavior | Risk Implication |
| Reactive | Intervene only when hematocrit exceeds target | Recurrent periods above threshold |
| Episodic Monitoring | Lab review aligned with visit schedule | Delayed identification of upward trends |
| Longitudinal Strategy | Structured monitoring cadence with predefined triggers | Sustained target maintenance |
| Integrated Risk Model | Combine hematocrit, symptom burden, and thrombotic risk factors | Holistic risk reduction |
The difference between models lies in anticipation rather than correction.
Why Variability Persists
Several factors contribute to fluctuating hematocrit control.
These drivers reflect performance architecture rather than knowledge deficits.
Designing Education Around Trajectory Thinking
CME addressing PV should incorporate longitudinal case simulations rather than single-visit scenarios. Participants can review serial hematocrit values over time and determine when earlier intervention would have reduced fluctuation.
Structured escalation frameworks are also essential. Education should clarify predefined triggers for therapy adjustment, reinforce risk stratification criteria, and integrate thrombotic risk awareness into routine decision making.
Competence assessment can require participants to identify the earliest appropriate escalation point in evolving cases. Performance evaluation may examine whether clinicians report increased monitoring frequency or earlier therapy modification after educational exposure.
Linking Control to Patient Impact
Sustained hematocrit control is not simply a numerical achievement. Thrombotic events in PV can lead to stroke, myocardial infarction, and other serious complications. By minimizing hematocrit variability over time, clinicians can reduce cumulative thrombotic risk exposure and shift disease management from reactive intervention toward preventive, longitudinal care.
From Recognition to Stability
PV presents a clear therapeutic target, but the greater challenge is maintaining hematocrit control consistently over time. CME that emphasizes trajectory-based monitoring, proactive escalation, and longitudinal management strategies may help close the gap between guideline recommendations and reliable real-world control.
